Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis

Journal of the National Medical Association

Volumn 97, Issue 8, 2005, Pages 1120-1126

  Samanci, Nehir ^a,b   Ozdem, Sebahat ^a,b   Akbas, Halide ^a,b   Mutlu, Derya ^a,b   Gultekin, Meral ^a,b   Arman, Mehmet ^a,b   Donmez, Levent ^a,b  

^a Akdeniz University School of Medicine ^*

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Anticyclic citrullinated; Disease activity parameters; Peptide; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

ACUTE PHASE PROTEIN; CITRULLINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISABILITY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HAND MALFORMATION; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE STIFFNESS; PAIN ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CITRULLINE; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUESTIONNAIRES; RHEUMATOID FACTOR; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 23244432438     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Shmerling RA, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. Am J Med. 1991;91:528-534.
2. Colglazier CL, Sutej PG. Laboratory testing in the rheumatic diseases: a practical review. South Med J.I 2005;98:185-191.
3. Dorner T, Egerer K, Feist E, et al. Rheumatoid factor revisited. Curr Opin Rheumatol. 2004;16:246-253.
4. Genevay S, Hayem G, Verpillat P, et al. An eight-year prospective study of outcome prediction by antiperinuclear factor and antikeratin antibodies at onset of rheumatoid arthritis. Ann Rheum Dis. 2002;61:734-736.
5. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000;2:236-243.
6. Kirstein H, Mathiesen FK. Antikeratin antibodies in rheumatoid arthritis. Methods and clinical significance. Scand J Rheumatol. 1987;16:331-338.
7. van Boekel MA, Vossenaar ER, van den Hoogen FH, et al. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res. 2002;4:87-93.
8. Bas S, Perneger TV, Seitz M, et al. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford). 2002; 41:809-814.
9. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380-386.
10. Schellekens GA, de Jong BAW, van den Hoogen FHJ, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101:273-281.
11. Schellekens GA, Visser H, de Jong BAW, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43:155-163.
12. Soderlin MK, Kastbom A, Kautiainen H, et al. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol. 2004;33:185-188.
13. Suzuki K, Sawada T, Murakami A, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol. 2003;32:197-204.
14. Zeng X, Ai M, Tian X, et al. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. Rheumatol. 2003; 30:1451-1455.
15. Bas S, Genevay S, Meyer O, et al. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford). 2003;42:677-680.
16. Bongi SM, Manetti R, Melchiorre D, et al. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity. 2004;37:495-501.
17. De Rycke L, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 2004;63:1587-1593.
18. Forslind K, Ahlmen M, Eberhardt K, et al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004;63:1090-1095.
19. Kastbom A, Strandberg G, Lindroos A, et al. Anti-CCP antibody test predicts the disease course during three years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis. 2004;63:1085-109.
20. Lindqvist E, Eberhardt K, Benutzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64:196-201.
21. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five-year radiographic damage. Ann Rheum Dis. 2003;62:120-126.
22. Scott DL, Symmons DP, Coulton BL et al. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987;1:1108-1111.
23. Houssien DA, Jonsson T, Davies E, et al. Clinical significance of IgA rheumatoid factor subclasses in rheumatoid arthritis. J Rheumatol. 1997;24: 2119-2122.
24. Houssien DA, Jonsson T, Davies E, et al. Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis. Scand J Rheumatol. 1998;27:46-53.
25. Knijff-Dutmer E, Drossaers-Bakker W, Verhoeven A, et al. Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage. Ann Rheum Dis. 2002;61:603-607.
26. Lucey MD, Newkirk MM, Neville C, et al. Association between IgM response to IgG damaged by glyoxidation and disease activity in rheumatoid arthritis. J Rheumatol. 2000;27:319-323.
27. Pinheiro GC, Scheinberg MA, Aparecida da Silva M, et al. Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med. 2003;139:234-235.
28. Vollbracht I, Rieber J, Oppermann M, et al. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis. 2004;63:1079-1084.
29. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
30. Kucukdeveci AA, Sahin H, Ataman S, et al. Issues in cross-cultural validity: example from the adaptation, reliability and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum. 2004;51:14-19.
31. De Rycke L, Verhelst X, Kruithof E, et al. Rheumatoid factor, but not anticyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005;64:299-302.
32. Pope RM, Lessard J, Nunnery E. Differential effects of therapeutic regimens on specific classes of rheumatoid factor. Ann Rheum Dis. 1986;45:183-189.
33. Scott DL, Dawes PT, Collins M, et al. ELISA assays for IgM and IgG rheumatoid factors: their clinical correlations during therapy with slow-acting anti-rheumatic drugs. Clin Rheumatol. 1987;6:358-368.
34. Davis P, Stein M, Ley H, et al. Serological profiles in the connective tissue diseases in Zimbabwean patients. Ann Rheum Dis. 1989;48:73-76.
35. Enzer I, Dunn G, Jacobsson L, et al. An epidemiologic study of trends in prevalence of rheumatoid factor seropositivity in Pima Indians: evidence of a decline due to both secular and birth-cohort influences. Arthritis Rheum. 2002;46:1729-1734.
36. Korpilahde T, Heliovaara M, Kaipiainen-Seppanen O, et al. Regional differences in Finland in the prevalence of rheumatoid factor in the presence and absence of arthritis. Ann Rheum Dis. 2003;62:353-355.
37. Padyukov L, Silva C, Stolt P, et al. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004;50:3085-3092.
38. Palosuo T, Tilvis R, Strandberg T, et al. Filaggrin-related antibodies among the aged. Ann Rheum Dis. 2003;62:261-263.
39. Bizzaro N, Mazzanti G, Tonutti E, et al. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem. 2001;47:1089-1093.
40. Mikuls TR, O'Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004;50:3776-3782.
41. Vasiliauskiene L, Wiik A, Hoier-Madsen M. Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis. Ann Rheum Dis. 2001;60:459-466.
42. Mallya RK, Young BJ, Pepys MB, et al. Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease. Clin Exp Immunol. 1983;51:17-20.